Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma
(LSE – AIM:SCLP.L), Unlocks path towards registrational Phase 3 trial planned to start in 2026 Data from Phase 2 SCOPE trial show iSCIB1+ has potential to redefine standard of care (SoC) iSCIB1+ shows an interim 24%-point improvement in progression free survival (PFS) over real world SoC and historic controls NOTTINGHAM, United Kingdom, Jan. 26, 2026 […]